Jason Shafrin, Ph.D.

Jason Shafrin, Ph.D., is a Senior Managing Director in FTI Consulting’s Center for Healthcare Economics and Policy, where he leads teams that apply advanced health economics and outcomes research (“HEOR”) methods to complex questions of pharmaceutical value, market access and policy. Dr. Shafrin has more than 20 years of experience advising global pharmaceutical and biotechnology companies, government agencies and nongovernmental organizations on evidence generation, pricing and reimbursement strategy, and the economic implications of policy and regulatory change.

Dr. Shafrin specializes in applied microeconomics and HEOR, including cost effectiveness and budget impact modeling, generalized risk adjusted cost effectiveness (“GRACE”) frameworks, discrete choice experiments and other stated preference methods, and real world evidence (“RWE”) studies using claims, registry and electronic health record data. He has led numerous engagements to quantify the value of innovative therapies and diagnostics; assess the impact of biosimilar and generic entry; design and evaluate alternative payment models; and measure spillover, insurance and equity effects that extend beyond traditional cost per QALY metrics.

In the context of disputes and litigation, Dr. Shafrin has provided economic analyses related to pricing and reimbursement decisions, as well as the competitive and policy environment for branded and generic/biosimilar products. He has conducted extensive work for U.S. and international public agencies, including technical reports for the Centers for Medicare & Medicaid Services and the Institute of Medicine on national health expenditure forecasting, value based purchasing, geographic variation and Medicare payment policy. This work has given him a deep understanding of how payers and regulators interpret and use economic evidence.

Dr. Shafrin’s research has been published in leading peer reviewed journals including BMJ Open, Health Affairs, Health Economics, Health Services Research, JAMA, the Journal of Managed Care & Specialty Pharmacy and Value in Health. These publications have spanned therapeutic areas such as oncology, neurology, cardiometabolic disease, rare disease and mental health. Beyond academic publishing, Dr. Shafrin is a recognized thought leader on pharmaceutical value and pricing policy. His commentary has appeared in outlets such as Forbes, Health Affairs Forefront, STAT News, U.S. News & World Report, the Wall Street Journal and the Washington Post. He has also been interviewed by National Public Radio, The Hill, Fortune and other media outlets on drug pricing, value based payment and access to innovation.

Dr. Shafrin is an Adjunct Professor at the University of Southern California’s Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. He is also the founder and editor of the Healthcare Economist blog, which has been consistently ranked among the top health and economics blogs globally.

Relevant Experience:

• Valued the societal and insurance benefits of treatments for Duchenne muscular dystrophy
• Developed GRACE models to measure the value of delaying mobility impairment across neurologic conditions
• Evaluated the economic impact of novel therapies under alternative payment models
• Advised on the use of RWE within the Medicare Drug Price Negotiation Program